Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.

Peciña M, Sikora M, Avery ET, Heffernan J, Peciña S, Mickey BJ, Zubieta JK.

Eur Neuropsychopharmacol. 2017 Oct;27(10):977-986. doi: 10.1016/j.euroneuro.2017.08.427. Epub 2017 Sep 1.

2.

Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.

Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, Gyertyán I, Duman RS.

Int J Neuropsychopharmacol. 2017 Oct 1;20(10):788-796. doi: 10.1093/ijnp/pyx038.

3.

Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review.

Pinna M, Manchia M, Oppo R, Scano F, Pillai G, Loche AP, Salis P, Minnai GP.

Neurosci Lett. 2018 Mar 16;669:32-42. doi: 10.1016/j.neulet.2016.10.047. Epub 2016 Oct 25. Review.

PMID:
27793702
4.

Role of nicotine dependence in the association between the dopamine receptor gene DRD3 and major depressive disorder.

Korhonen T, Loukola A, Wedenoja J, Nyman E, Latvala A, Broms U, Häppölä A, Paunio T, Schrage AJ, Vink JM, Mbarek H, Boomsma DI, Penninx BW, Pergadia ML, Madden PA, Kaprio J.

PLoS One. 2014 Jun 13;9(6):e98199. doi: 10.1371/journal.pone.0098199. eCollection 2014.

5.

Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression.

Pearson-Fuhrhop KM, Dunn EC, Mortero S, Devan WJ, Falcone GJ, Lee P, Holmes AJ, Hollinshead MO, Roffman JL, Smoller JW, Rosand J, Cramer SC.

PLoS One. 2014 May 16;9(5):e93772. doi: 10.1371/journal.pone.0093772. eCollection 2014.

6.

Gene environment interaction studies in depression and suicidal behavior: An update.

Mandelli L, Serretti A.

Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 1):2375-97. doi: 10.1016/j.neubiorev.2013.07.011. Epub 2013 Jul 22. Review.

PMID:
23886513
7.

DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder.

Savitz J, Hodgkinson CA, Martin-Soelch C, Shen PH, Szczepanik J, Nugent AC, Herscovitch P, Grace AA, Goldman D, Drevets WC.

Int J Neuropsychopharmacol. 2013 Oct;16(9):2095-101. doi: 10.1017/S146114571300045X. Epub 2013 May 20.

8.

The functional DRD3 Ser9Gly polymorphism (rs6280) is pleiotropic, affecting reward as well as movement.

Savitz J, Hodgkinson CA, Martin-Soelch C, Shen PH, Szczepanik J, Nugent A, Herscovitch P, Grace AA, Goldman D, Drevets WC.

PLoS One. 2013;8(1):e54108. doi: 10.1371/journal.pone.0054108. Epub 2013 Jan 24.

9.

DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study.

Tsuchimine S, Yasui-Furukori N, Nakagami T, Sato Y, Kaneko S.

J Clin Psychopharmacol. 2012 Oct;32(5):724-6. doi: 10.1097/JCP.0b013e318267b6da. No abstract available.

PMID:
22926616
10.

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.

Perlis RH, Fijal B, Dharia S, Houston JP.

Pharmacogenomics J. 2013 Jun;13(3):280-5. doi: 10.1038/tpj.2011.62. Epub 2012 Jan 17.

PMID:
22249355
11.

Dopamine D₃ receptor gene variation: impact on electroconvulsive therapy response and ventral striatum responsiveness in depression.

Dannlowski U, Domschke K, Birosova E, Lawford B, Young R, Voisey J, Morris CP, Suslow T, Konrad C, Kugel H, Ohrmann P, Bauer J, Schöning S, Zavorotnyy M, Diemer J, Arolt V, Baune BT, Zwanzger P.

Int J Neuropsychopharmacol. 2013 Aug;16(7):1443-59. doi: 10.1017/S1461145711001659. Epub 2011 Nov 18.

PMID:
22093107
12.

Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response.

Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L.

J Affect Disord. 2011 Sep;133(1-2):165-73. doi: 10.1016/j.jad.2011.04.011. Epub 2011 Jun 16.

PMID:
21680027
13.

A follow-up case-control association study of tractable (druggable) genes in recurrent major depression.

Schosser A, Gaysina D, Cohen-Woods S, Domenici E, Perry J, Tozzi F, Korszun A, Gunasinghe C, Gray J, Jones L, Binder EB, Holsboer F, Craddock N, Owen MJ, Craig IW, Farmer AE, Muglia P, McGuffin P.

Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):640-50. doi: 10.1002/ajmg.b.31204. Epub 2011 May 31.

PMID:
21630437
14.

Preliminary evidence for an association between a dopamine D3 receptor gene variant and obsessive-compulsive personality disorder in patients with major depression.

Light KJ, Joyce PR, Luty SE, Mulder RT, Frampton CM, Joyce LR, Miller AL, Kennedy MA.

Am J Med Genet B Neuropsychiatr Genet. 2006 Jun 5;141B(4):409-13.

PMID:
16583407
15.

Strain differences in the distribution of dopamine (DA-2 and DA-3) receptor sites in rat brain.

Yaroslavsky I, Colletti M, Jiao X, Tejani-Butt S.

Life Sci. 2006 Jul 17;79(8):772-6. Epub 2006 Mar 30.

PMID:
16574158
16.

Lack of association between polymorphisms of dopamine receptors, type D2, and bipolar affective illness in a Polish population.

Leszczyńska-Rodziewicz A, Hauser J, Dmitrzak-Weglarz M, Skibińka M, Czerski P, Zakrzewska A, Kosmowska M, Rybakowski JK.

Med Sci Monit. 2005 Jun;11(6):CR289-295. Epub 2005 May 25.

PMID:
15917720
17.

Dopaminergic mechanism of antidepressant action in depressed patients.

Willner P, Hale AS, Argyropoulos S.

J Affect Disord. 2005 May;86(1):37-45.

PMID:
15820269
18.

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK.

Biol Psychiatry. 2004 Jul 1;56(1):54-60.

PMID:
15219473
19.
20.

Effect of combined treatment with imipramine and amantadine on the central dopamine D2 and D3 receptors in rats.

Rogóz Z, Dlaboga D, Dziedzicka-Wasylewska M.

J Physiol Pharmacol. 2003 Jun;54(2):257-70.

Supplemental Content

Loading ...
Support Center